Review
(722) Total Article Views
Authors: Ridolo E, Montagni M, Olivieri E, Riario-Sforza GG, Incorvaia C
Published Date September 2013 Volume 2013:8 Pages 425 - 432
DOI: http://dx.doi.org/10.2147/COPD.S49179
| Received: | 29 May 2013  |
|---|---|
| Accepted: | 01 August 2013 |
| Published: | 18 September 2013 |
1Department of Clinical and Experimental Medicine, University of Parma, Parma, 2Pulmonary Rehabilitation Unit, ICP Hospital, Milan, Italy
Abstract: Bronchodilators are central drugs in the management of patients with chronic obstructive pulmonary disease (COPD). Indacaterol was the first agent of the novel family of very long-acting β2-agonists to be used as an inhaled bronchodilator for COPD and provides 24-hour therapeutic action, thus allowing once-daily administration. Data from clinical trials show that indacaterol has a bronchodilator effect similar to that of the anticholinergic tiotropium bromide and slightly higher efficacy compared with the long-acting β2-agonists, salmeterol and formoterol. Moreover, the safety profile is excellent and comparable with that of placebo. Concerning adherence with drug treatment and real-life management in respect to long-acting β2-agonists, once-daily dosing makes indacaterol more convenient for COPD patients and is likely to enhance patient adherence. Other very long-acting β2-agonists currently in development include vilanterol, olodaterol, and carmoterol, and these have shown good characteristics for clinical use in the studies reported thus far.
Keywords: chronic obstructive pulmonary disease, bronchodilators, very long-acting β2-agonists
Post to:
CannoteaCiteulikeDel.icio.usFacebookLinkedInTwitter
No comments:
Post a Comment